# A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer

> **NCT07591597** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **National Cancer Center Hospital East** · enrollment: 68 (estimated)

## Conditions studied

- Metastatic Colorectal Neoplasms
- Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer

## Interventions

- **BIOLOGICAL:** S-531011
- **DRUG:** Fruquintinib
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07591597
- **Lead sponsor:** National Cancer Center Hospital East
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-07
- **Final completion:** 2029-05
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07591597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07591597, "A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07591597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*